Study Could Weaken Merck's Vioxx Defense: Report

Law360, New York (July 3, 2007, 12:00 AM EDT) -- A new study which reportedly lends credibility to evidence that Merck & Co.'s Vioxx increased the risk of heart attacks in patients immediately after they started taking the drug could drive a stake into the pharmaceutical giant's mostly favorable track record in litigation over the ill-fated painkiller.

The study, which is slated to be published in the New England Journal of Medicine, was conducted by researchers at Oxford University in England in order to determine whether the drug would curb progression of colon cancer, the Wall...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.